{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/asthma/how-up-to-date-is-this-topic/update/","result":{"pageContext":{"chapter":{"id":"a993bde1-1ac8-529e-8a3e-201a8c082ab2","slug":"update","fullItemName":"Update","depth":2,"htmlHeader":"<!-- begin field 11cbb9d8-5b51-44e4-a524-b7e240dfdf11 --><h2>Update</h2><!-- end field 11cbb9d8-5b51-44e4-a524-b7e240dfdf11 -->","summary":null,"htmlStringContent":"<!-- begin item 2ffa2492-015d-4b65-97d4-25a6a535c449 --><!-- end item 2ffa2492-015d-4b65-97d4-25a6a535c449 -->","topic":{"id":"d631356f-d3a3-51fb-807c-5517c470a5af","topicId":"2a0a90e6-1c4e-4b6a-9ce2-3379dd122594","topicName":"Asthma","slug":"asthma","lastRevised":"Last revised in October 2020","chapters":[{"id":"c7185669-75fd-5c6e-b105-63a3237634ac","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"9fe1ab10-4b4d-5ba8-9ef0-00631cd00ea4","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"770d55df-2c61-5d1e-83d9-92b12ccae96a","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d2031db2-44fd-55bb-b5c8-d085b387747a","slug":"changes","fullItemName":"Changes"},{"id":"a993bde1-1ac8-529e-8a3e-201a8c082ab2","slug":"update","fullItemName":"Update"}]},{"id":"eae8fe92-3941-512e-bcc6-f1e15157c1ae","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"8e125759-cd9d-510d-9659-3c2e77baa755","slug":"goals","fullItemName":"Goals"},{"id":"a6c91cd5-1ce2-5c60-86cc-341a9dccf3d4","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"a5746054-2f36-5a42-9e7c-7af9107ad99b","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"5fd19cd9-6ac7-54c8-89be-817d58e41309","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"f7339086-c653-53dd-990c-6d470fa223b8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"f43b79db-3c62-58ee-bb70-932e6613eea6","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"0d12a387-5436-5c75-92c0-189cb391ec7a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"8fbe04ed-5fd7-54c9-be84-6c959f75af3b","slug":"definition","fullItemName":"Definition"},{"id":"5cbe6206-f80c-5a71-8e4d-a4d44e392874","slug":"prevalence","fullItemName":"Prevalence"},{"id":"2fb588ab-6181-5aec-8a4a-fb368098329d","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"b786654f-5e6e-5e5f-9ead-abaca7f99ba5","slug":"prognosis","fullItemName":"Prognosis"},{"id":"c0b65c0b-957e-538e-83e9-5b4af2d8e6dd","slug":"complications","fullItemName":"Complications"}]},{"id":"574c6193-f36f-5bf7-946a-d8c688476131","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"351773e5-286c-5560-8402-79c2d92d4aa6","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"053272da-fea9-5df6-842a-0de682896aaf","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"7b632c20-012f-590e-a01e-cda5715d6f14","fullItemName":"Management","slug":"management","subChapters":[{"id":"f95fb73f-b749-53a5-b857-4d2bb9945667","slug":"newly-diagnosed-asthma","fullItemName":"Scenario: Newly-diagnosed asthma"},{"id":"2878c5f8-3e3f-52c8-a9bd-7988906b6f99","slug":"follow-up","fullItemName":"Scenario: Follow-up"},{"id":"2458c073-8efb-5a81-8bc4-9a543deab17d","slug":"acute-exacerbation-of-asthma","fullItemName":"Scenario: Acute exacerbation of asthma"},{"id":"45a1b06c-1e5d-56b4-8da7-a8abf4f6c7cc","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"fb9dc424-4306-54a1-b06b-1b01273ac473","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"52940123-8084-55c3-b593-cc9fe50daf8f","slug":"azithromycin","fullItemName":"Azithromycin"},{"id":"5eb1288c-29af-59c1-b623-bd0010732835","slug":"beta-2-agonists","fullItemName":"Beta-2 agonists"},{"id":"dc8f7545-ff7a-5bf1-8ac8-95161137fac5","slug":"inhaled-corticosteroids","fullItemName":"Inhaled corticosteroids"},{"id":"4d715496-c821-52e3-8ea0-d05cfb33d3eb","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"},{"id":"d8174f33-d787-5076-88b5-f4c67df93128","slug":"leukotriene-receptor-antagonists","fullItemName":"Leukotriene receptor antagonists"},{"id":"a556cd4f-1851-52fd-a993-34e977a27fd2","slug":"muscarinic-agents","fullItemName":"Muscarinic agents"},{"id":"0cea3b69-b77b-505e-bded-6fceaca145df","slug":"theophylline","fullItemName":"Theophylline"},{"id":"550429f1-7cab-5f16-b476-e479d8084c03","slug":"cromones","fullItemName":"Cromones"}]},{"id":"76b3dfce-ba54-5456-a259-79b345a5e064","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"e31b3681-17cc-5ff2-ba28-d3b1fcb0a82c","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2bcf3eeb-fd2e-5d40-a52f-da626afbbe01","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"14ea4312-4846-5381-a82c-dc6b03a60d04","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"e4987bc8-0a78-59eb-bfda-f9de7c9ee182","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"be4f3045-8192-53b7-81a3-b460bb2218bc","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"82ae443c-942c-5053-a988-38bce8dec570","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"efdf3cf8-dee5-5351-9d2d-346b4fdf9faf","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"770d55df-2c61-5d1e-83d9-92b12ccae96a","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"221ff4ef-ed04-55a5-8f46-4db55e9e3720","slug":"new-evidence","fullItemName":"New evidence","depth":3,"htmlHeader":"<!-- begin field 85cc18d3-794f-4ac7-85c7-89b7c2f3a7b9 --><h3>New evidence</h3><!-- end field 85cc18d3-794f-4ac7-85c7-89b7c2f3a7b9 -->","summary":null,"htmlStringContent":"<!-- begin item ccba3ee6-8ec7-4867-b4d6-d9d150b81fcc --><!-- begin field d4ac5b43-f76e-4bb7-a782-2cf3b178fb22 --><h3>Evidence-based guidelines</h3><!-- end field d4ac5b43-f76e-4bb7-a782-2cf3b178fb22 --><!-- begin field 2ecf291a-a6ac-4cae-bf7a-120ba845bbfb --><ul><li>Gonem, S., Cumella, A., and Richardson, M. (2019) <em>Asthma admission rates and patterns of salbutamol and inhaled corticosteroid prescribing in England from 2013 to 2017. </em>BMJ Journals. <a href=\"https://thorax.bmj.com/\" data-hyperlink-id=\"8313f3f3-a9b2-4dde-83df-a9de00a44c58\">www.throrax.bmj.com</a> [<a href=\"https://thorax.bmj.com/content/early/2019/01/10/thoraxjnl-2018-212723\" data-hyperlink-id=\"77ac9640-cd35-4202-a1e3-a9de00a44c72\">Free Full-text</a>]</li><li>Girling, J. (2020) <em>Prescribing for pregnancy: asthma.</em> Drug and Therapeutics Bulletin. <a href=\"https://dtb.bmj.com/\" data-hyperlink-id=\"851098bf-5cb4-4b9c-97dc-ab7300b07bcf\">www.dtb.bmj.com</a> [<a href=\"https://dtb.bmj.com/content/58/3/41.info\" data-hyperlink-id=\"abdc5b74-a947-4f6f-85fb-ab7300b07bdb\">Abstract</a>]</li><li>McKee, S. (2020) <em>High-dose enerzair breezhaler further cuts asthma exacerbations.</em> <a href=\"http://www.pharmatimes.com/\" data-hyperlink-id=\"bffc855f-fc72-4d3d-88f9-ac3300d3dd16\">www.PharmaTimes.com</a> [<a href=\"http://www.pharmatimes.com/news/high-dose_enerzair_breezhaler_further_cuts_asthma_exacerbations_1348771\" data-hyperlink-id=\"093630c5-f5e4-4bd8-8a1b-ac3300d3dd25\">Free Full-text</a>] </li><li>Cloutier, M.M., Dixon, A.E., Krishnan, J.A., et al. (2020) <em>Managing asthma in adolescents and adults 2020 asthma guideline update from the National Asthma Education and Prevention Program</em>. JAMA. <a href=\"https://jamanetwork.com/\" data-hyperlink-id=\"b4d16b8e-43ac-4bee-85bf-ac9400eda918\">www.jamanetwork.com</a> [<a href=\"https://jamanetwork.com/journals/jama/fullarticle/2773482\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"76651880-e4ff-4dd7-99d7-ac9400eda918\">Free Full-text</a>]</li><li>Healthy London Partnership (2021) <em>Transforming the care of children and young people in London with asthma: development of the London Asthma Standards.</em> <a href=\"https://www.nice.org.uk/\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"626b6a61-04ca-474c-874d-acc600ef40ef\">www.nice.org.uk</a> [<a href=\"https://www.nice.org.uk/sharedlearning/transforming-care-cyp-london-with-asthma\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"2ea5980f-f2d2-438e-b97d-acc600ef40ef\">Free Full-text</a>]</li></ul><!-- end field 2ecf291a-a6ac-4cae-bf7a-120ba845bbfb --><!-- begin field 6f9164f0-9a49-4d29-a6cf-577f3c2f7c18 --><h3>HTAs (Health Technology Assessments)</h3><!-- end field 6f9164f0-9a49-4d29-a6cf-577f3c2f7c18 --><!-- begin field 376d4673-5268-489e-a713-361578d59e14 --><ul><li>NICE (2019) <em>TA565: Benralizumab for treating severe eosinophilic asthma. </em>National Institute for Health and Care Excellence. <a href=\"https://www.nice.org.uk/\" data-hyperlink-id=\"4f25976e-5faa-4d65-b31e-aa1400fdaabd\">www.nice.org.uk</a> [<a href=\"https://www.nice.org.uk/guidance/ta565\" data-hyperlink-id=\"6c97a9b1-fa6e-440f-b80b-aa1400fdaae6\">Free Full-text</a>]</li></ul><!-- end field 376d4673-5268-489e-a713-361578d59e14 --><!-- begin field 28caae71-77ac-4f16-876f-e39ab0370d0f --><h3>Economic Appraisals</h3><!-- end field 28caae71-77ac-4f16-876f-e39ab0370d0f --><!-- begin field 9b5e8257-d218-4f01-b85b-843b29ac76da --><p>No new economic appraisals relevant to England since 1 March 2018.</p><!-- end field 9b5e8257-d218-4f01-b85b-843b29ac76da --><!-- begin field d010b39d-e314-421d-b607-8bedeb8acf23 --><h3>Systematic reviews and meta-analyses</h3><!-- end field d010b39d-e314-421d-b607-8bedeb8acf23 --><!-- begin field 878f5ba4-b08c-4bd4-83c1-1e667a7d2995 --><ul><li>Asthma UK (2018) <em>UK asthma death rates among worst in Europe.</em> Asthma UK. <a href=\"https://www.asthma.org.uk//\" data-hyperlink-id=\"dfc1792b-fbef-4172-8929-a8f70155eb8d\">www.asthma.org.uk</a> [<a href=\"https://www.asthma.org.uk/about/media/news/press-release-uk-asthma-death-rates-among-worst-in-europe/\" data-hyperlink-id=\"54671c84-5307-48ad-a258-a8f70155ebfa\">Free Full-text</a>]</li><li>BMJ (2018) <em>Two pathways, one patient; UK asthma guidelines</em>. British Medical Journal. <a href=\"http://journals.bmj.com/\" data-hyperlink-id=\"d7083764-35c0-452e-8c14-a8f70155ec36\">www.bmj.com</a> [<a href=\"http://thorax.bmj.com/content/early/2018/05/02/thoraxjnl-2018-211703\" data-hyperlink-id=\"3504c43f-f5a3-4dfa-a6b5-a8f70155ec44\">Free Full-text</a>]</li><li>BMJ (2018) <em>Improving the global diagnosis and management of asthma in children</em>. British Medical Journal. <a href=\"https://journals.bmj.com/\" data-hyperlink-id=\"139b6155-9001-40e0-bcde-a90000ad25ce\">www.bmj.com</a> [<a href=\"http://thorax.bmj.com/content/73/7/662\" data-hyperlink-id=\"37f051ff-df5d-48fe-974f-a90000ad25d3\">Free Full-text</a>]</li><li>Busse, W., et al. (2018) <em>Combined analysis of asthma safety trails of long-acting ß<sub>2</sub>-agonists</em>. The New England Journal of Medicine. <a href=\"https://www.nejm.org/\" data-hyperlink-id=\"ba3e256a-52be-4229-80e3-a915009caf6f\">www.nejm.org</a> [<a href=\"https://www.nejm.org/doi/full/10.1056/NEJMoa1716868\" data-hyperlink-id=\"e52796f8-f97e-4059-8aeb-a915009cb104\">Free Full-text</a>]</li><li>NIHR (2018) <em>Increasing inhaled steroids for short periods reduces asthma exacerbations</em>. National Institute for Health Research [<a href=\"https://discover.dc.nihr.ac.uk/content/signal-000619/asthma-exacerbations-can-be-reduced-by-increasing-inhaled-steroids-for-short-periods\" data-hyperlink-id=\"130338e3-c5ac-4b67-8dac-a92700cb13c4\">Free Full-text</a>]</li><li>Connett, G., Connett, L., and Thomas, M. (2019) <em>Determining the reasons for poorly controlled asthma in an adolescent.</em> British Medical Journal. <a href=\"https://www.bmj.com/\" data-hyperlink-id=\"5f871a76-41c3-4ecc-8224-a9e400a6af24\">www.bmj.com</a> [<a href=\"https://www.bmj.com/content/364/bmj.l75\" data-hyperlink-id=\"d6ea5fc6-c64b-4e05-8883-a9e400a6af31\">Free Full-text</a>]</li><li>Stefan, M., Shieh, M-S., and Spitzer, K. (2019) <em>Association of Antibiotic Treatment With Outcomes in Patients Hospitalized for an Asthma Exacerbation Treated With Systemic Corticosteroids. </em>JAMA Internal Medicine. <a href=\"https://jamanetwork.com/\" data-hyperlink-id=\"2f0a8b09-ce8a-485a-966d-a9fc00b3d2bf\">www.jamanetwork.com</a> [<a href=\"https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2721036\" data-hyperlink-id=\"26aefe49-015c-42a3-8c99-a9fc00b3d366\">Free Full-text</a>]</li><li>Shaw, D., Gaynor, M. and Fogarty, A. (2019) <em>Changes in asthma mortality in England and Wales since 2001.</em> BMJ Journals. <a href=\"https://thorax.bmj.com/\" data-hyperlink-id=\"90ec5489-d73f-4d42-bf58-aae2009a4d8e\">www.thorax.bmj.com</a> [<a href=\"https://thorax.bmj.com/content/early/2019/09/12/thoraxjnl-2019-213350\" data-hyperlink-id=\"52c22566-7ae3-4cd7-995c-aae2009a4da9\">Free Full-text</a>]</li><li>Craig, S.S., Dalziel, S.R., Powell, C.V.E., et al. (2020) <em>Interventions for escalation of therapy for acute exacerbations of asthma in children: an overview of Cochrane Reviews.</em> <a href=\"https://www.cochranelibrary.com/\" data-hyperlink-id=\"ce86a459-c944-4336-a952-ac1000d35396\">www.cochranelibrary.com</a> [<a href=\"https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012977.pub2/full\" data-hyperlink-id=\"fbc59455-d783-419b-a82d-ac1000d35473\">Free Full-text</a>]</li><li>Hodkinson, A., Bower, P., Grigoroglou, C. et al. (2020) <em>Self-management interventions to reduce healthcare use and improve quality-of-life among patients with asthma: systematic review and network meta-analysis.</em> BMJ. <a href=\"https://www.bmj.com/content/370/bmj.m2521\" data-hyperlink-id=\"9cfec62c-b584-467b-90a7-ac1e00b7b7e1\">www.bmj.com</a> [<a href=\"https://www.bmj.com/content/370/bmj.m2521\" data-hyperlink-id=\"642ed0be-4417-4cef-a4b9-ac1e00b7b7ef\">Free Full-text</a>]</li></ul><!-- end field 878f5ba4-b08c-4bd4-83c1-1e667a7d2995 --><!-- begin field d6921492-b70d-4710-8132-c7fff72e16e7 --><h3>Primary evidence</h3><!-- end field d6921492-b70d-4710-8132-c7fff72e16e7 --><!-- begin field 5eeb24b3-ecd0-447d-8d1d-9529901869b8 --><ul><li>NEJM (2018) Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. The New England Journal of Medicine. <a href=\"https://www.nejm.org/\" data-hyperlink-id=\"4b2d057e-7152-4207-999c-a8f701555ba1\">www.nejm.org</a> [<a href=\"https://www.nejm.org/doi/full/10.1056/NEJMoa1804092\" data-hyperlink-id=\"2365fe0f-0a32-4a88-99eb-a8f701555d59\">Free Full-text</a>]</li><li>Biospace Inc. (2018) GSK announces long-term data on mepolizumab in patients with severe asthma. Biospace Inc. <a href=\"https://www.biospace.com/\" data-hyperlink-id=\"f30bdce7-26c2-4f84-8bb3-a8f701555f18\">www.biospace.com</a> [<a href=\"https://www.biospace.com/article/gsk-unveils-positive-long-term-nucala-data-for-patients-with-severe-asthma/?keywords=MEPOLIZUMAB\" data-hyperlink-id=\"1ad06d27-716f-45e7-9e5c-a8f701555fb2\">Free Full-text</a>]</li><li>Bloom, C.I., Caberea, C., Arnetorp, S. et al. (2020) <em>Asthma-related health outcomes associated with short-acting ß2-agonist inhaler use: an observational UK study as part of the SABINA global program.</em> Advances in Therapy. <a href=\"https://link.springer.com/\" data-hyperlink-id=\"b70f24ce-5df3-4bc8-95f6-ac1e00b9a4f7\">www.link,springer.com</a> [<a href=\"https://link.springer.com/article/10.1007/s12325-020-01444-5\" data-hyperlink-id=\"6e3b86d6-deeb-41a2-8d31-ac1e00b9a545\">Free Full-text</a>]</li></ul><!-- end field 5eeb24b3-ecd0-447d-8d1d-9529901869b8 --><!-- end item ccba3ee6-8ec7-4867-b4d6-d9d150b81fcc -->","subChapters":[]},{"id":"bd76b874-84e9-5fdf-9787-64304b4de3ee","slug":"new-policies","fullItemName":"New policies","depth":3,"htmlHeader":"<!-- begin field 4e3749ed-2b76-45af-b0a9-f4ec4e067624 --><h3>New policies</h3><!-- end field 4e3749ed-2b76-45af-b0a9-f4ec4e067624 -->","summary":null,"htmlStringContent":"<!-- begin item 45f88529-1d86-428f-a15c-16786d01b685 --><!-- begin field 3cbff26b-704b-4d88-bef4-90ab9b7271f9 --><p>No new national policies or guidelines since 1 March 2018.</p><!-- end field 3cbff26b-704b-4d88-bef4-90ab9b7271f9 --><!-- end item 45f88529-1d86-428f-a15c-16786d01b685 -->","subChapters":[]},{"id":"bd028273-3892-52a3-91b9-d264b5c8aca9","slug":"new-safety-alerts","fullItemName":"New safety alerts","depth":3,"htmlHeader":"<!-- begin field 647f87e3-4264-4eee-9072-b3ac62ac67f6 --><h3>New safety alerts</h3><!-- end field 647f87e3-4264-4eee-9072-b3ac62ac67f6 -->","summary":null,"htmlStringContent":"<!-- begin item 7017c19c-71fa-4b79-9195-554804021d1c --><!-- begin field 74539bdf-ef7f-44e2-92be-0888d85fb494 --><p>No new safety alerts since 1 March 2018.</p><!-- end field 74539bdf-ef7f-44e2-92be-0888d85fb494 --><!-- end item 7017c19c-71fa-4b79-9195-554804021d1c -->","subChapters":[]},{"id":"e632d734-d567-576e-89e3-71cfd6d7baa9","slug":"changes-in-product-availability","fullItemName":"Changes in product availability","depth":3,"htmlHeader":"<!-- begin field 866df228-f9ab-4341-8761-cd96551e03ab --><h3>Changes in product availability</h3><!-- end field 866df228-f9ab-4341-8761-cd96551e03ab -->","summary":null,"htmlStringContent":"<!-- begin item 09c12594-d1ed-47f4-8faf-1c4bc3a69d8f --><!-- begin field 72cbd259-65b4-4346-a11d-792e6b742b34 --><ul><li>Spiriva Respimat 2.5 microgram, inhalation solution is now licensed as an add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma who experienced one or more severe asthma exacerbations in the preceding year. See more <a href=\"https://www.medicines.org.uk/emc/product/407/smpc\" data-hyperlink-id=\"9b4529f6-fabf-4540-b807-a8f7014d6f94\">here</a>.</li><li>UK launch of Flutiform k-haler for asthma. Flutiform k-haler is the first breath-actuated inhaled corticosteroid long-acting beta-<sub>2</sub> agonist combination aerosol inhaler for adults and adolescents. The device is activated by a low breathing-in force that makes it easier to use correctly. See more <a href=\"http://www.pharmatimes.com/news/uk_first_eu_nation_to_launch_flutiform_k-haler_for_asthma_1251730\" data-hyperlink-id=\"81266755-f5b5-413f-9a48-a96700ad146c\">here</a>. </li><li>The SPC for Fostair (beclomethasone and formoterol) NEXThaler 100/6 has been updated to add maintenance and reliever treatment (MART) posology in asthma. The MART regimen is in line with the Fostair 100/6 aerosol device (1 puff as needed as rescue treatment, up to a maximum daily dose of 8 inhalations). See more <a href=\"https://www.medicines.org.uk/emc/product/3317/smpc\" data-hyperlink-id=\"7e4304de-0234-4703-9c4a-a98f009c390d\">here</a>. </li><li>The SPCs for Flutiform 50/5 and 125/5 microgram (fluticasone/formoterol) actuation pressurised inhalation, suspension have been updated following the addition of a new paediatric indication for children aged 5 to less than 12 for the treatment of asthma. See more <a href=\"https://www.medicines.org.uk/emc/product/7649/smpc\" data-hyperlink-id=\"cb4e30f3-d4cf-4f8a-9f60-a9d600f62e3c\">here</a>. </li><li>European CHMP recommends dupilumab for adult and adolescent (12 years and older) patients with certain forms of severe asthma. See more <a href=\"https://www.ema.europa.eu/en/news/new-add-treatment-patients-severe-asthma\" data-hyperlink-id=\"c21503b6-6a60-4691-b33d-aa1400ce6126\">here</a>. </li><li>Mepolizumab (Nucala®) accepted for restricted use in children over 6 years within NHSScotland - SMC has accepted mepolizumab as add-on treatment for severe refractory eosinophilic asthma in children >6 years. Use is restricted to those who have >150cells/microlitre eosinophils at initiation and >4 exacerbations in preceding year or receiving maintenance oral corticosteroids. See more <a href=\"https://www.scottishmedicines.org.uk/medicines-advice/mepolizumab-nucala-abbreviated-smc2139/\" data-hyperlink-id=\"50d74f16-61bb-4a3d-a5eb-aa5500d00041\">here</a>.</li><li>Dupilumab is now licensed for patients >12 years as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or FeNO, who are inadequately controlled with high dose ICS+another medicinal product for maintenance treatment. See more <a href=\"https://www.medicines.org.uk/emc/product/8553/smpc\" data-hyperlink-id=\"1ac11324-6454-4f27-83e4-aa57009249ed\">here</a>. </li><li>Nucala (mepolizumab) 100 mg solution for injection in pre-filled syringe, new subcutaneous formulations can be administered by the patient, and are licensed as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older. The recommended dose is 100 mg every 4 weeks. See more <a href=\"https://www.medicines.org.uk/emc/product/10564/smpc\" data-hyperlink-id=\"031e99af-16f8-4e22-9483-aaa900bcb2f7\">here</a>. </li><li>NICE has recommended benralizumab, as an add-on therapy, for severe eosinophilic asthma that is inadequately controlled in adults despite maintenance therapy with high-dose inhaled corticosteroids and long-acting beta-agonists, if certain conditions are met. See more <a href=\"https://www.nice.org.uk/guidance/ta565\" data-hyperlink-id=\"8f3589d5-07c9-474b-953e-aace00d8b740\">here</a>.</li><li>European CHMP recommends indacaterol, glycopyrronium, mometasone for maintenance treatment of asthma in adults. It is intended for use in adults inadequately controlled with maintenance long-acting beta-<sub>2</sub> agonist and high-dose inhaled corticosteroid who experienced ≥1 exacerbation in the previous year. See more <a href=\"https://www.ema.europa.eu/en/medicines/human/summaries-opinion/enerzair-breezhaler\" data-hyperlink-id=\"d94b60fa-a5f4-40cf-b663-abb4009bcbaa\">here</a>.</li><li>Symbicort, 100 micrograms budesonide/3 micrograms formoterol/actuation pressurized inhalations, suspension, is licensed for use in adults and adolescents for regular treatment of asthma, where use of combination (inhaled corticosteroid and long-acting beta-<sub>2</sub> adrenoreceptor agonist) is appropriate. See more <a href=\"https://www.medicines.org.uk/emc/product/11855/smpc\" data-hyperlink-id=\"6ecd09b2-fa61-446c-9ae8-ac6b00cc4d2e\">here</a>. </li></ul><!-- end field 72cbd259-65b4-4346-a11d-792e6b742b34 --><!-- end item 09c12594-d1ed-47f4-8faf-1c4bc3a69d8f -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}